Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly and CompanyEli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge CNBCLilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk ReutersLilly Boosts Sales Guidance on Strong Demand for Obesity Drugs Bloomberg.com
|